Polygonatum cyrtonema polysaccharides reshape the gut microbiota to ameliorate dextran sodium sulfate-induced ulcerative colitis in mice

Chaoyou Lin, Song Dawei, Shangwen Wang, Yunfei Chu, Changxing Chi, Sining Jia, Mengyi Lin, Chenbei He, Chengxi Jiang, Fanghua Gong, Qiongzhen ChenFrontiers in Pharmacology 2024 · DOI

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by inflammatory imbalance, intestinal epithelial mucosal damage, and dysbiosis of the gut microbiota. Polygonatum cyrtonema polysaccharides (PCPs) can regulate gut microbiota and inflammation. This study investigated the effects of whole PCPs and their fractions (PCP-1 and PCP-2) on dextran sodium sulfate (DSS)-induced UC mice. Results revealed that PCP treatment significantly optimized weight loss and colon shortening, restored inflammatory balance, mitigated oxidative stress, and repaired intestinal epithelial damage. The whole PCPs exhibited superior efficacy compared to fractions. Furthermore, the therapeutic effects were diminished upon gut microbiota depletion with antibiotics, while fecal microbiota transplantation (FMT) from PCP-treated mice replicated the benefits, indicating that the gut microbiota partially mediates the therapeutic effects of PCPs.

Introduction

Ulcerative colitis is a debilitating chronic inflammatory bowel disease characterized by a "leaky" intestinal barrier, runaway inflammation, and microbial dysbiosis. While current treatments like corticosteroids and immunosuppressants are available, they often carry severe side effects. Natural polysaccharides, such as those from Polygonatum cyrtonema (Sealwort), have emerged as potential safer alternatives. This research explores whether PCPs work directly on the host or indirectly by modulating the gut ecosystem, and whether the whole extract outperforms isolated molecular weight fractions—a key question for drug standardization.

Methods

The study utilized a DSS-induced UC mouse model and employed several experimental strategies:

  • Fractionation: PCPs were separated into PCP-1 (19.9 kDa) and PCP-2 (71.6 and 4.2 kDa) to compare against the whole extract.
  • Microbiota Depletion: An antibiotic cocktail (ABX) was used to deplete gut bacteria before PCP treatment to assess the necessity of the microbiota.
  • Fecal Microbiota Transplantation (FMT): Microbiota from PCP-treated mice was transferred to untreated UC mice to see if the bacteria alone could carry the therapeutic effect.
  • Multi-omics Analysis: 16S rRNA sequencing and untargeted LC-MS metabolomics were used to profile bacterial species and chemical changes in the gut.

Results

Phenotypic Recovery

PCP treatment significantly mitigated the clinical symptoms of UC. Specifically, it reduced weight loss and prevented the colon shortening typically observed in DSS-induced models. Interestingly, the unfractionated (whole) PCPs showed superior therapeutic efficacy compared to the isolated PCP-1 or PCP-2 fractions, suggesting a synergistic effect between different polysaccharide structures.

Initial weight change (%) across different treatment groups.
Colon length (cm) measurements showing recovery with PCP treatment.

Microbiota as the Essential Mediator

The most critical finding was that when gut bacteria were depleted via antibiotics, the protective effects of PCPs largely vanished. This proves that PCPs don't just "fix" the host; they "feed" the right bacteria to do the fixing. PCP treatment specifically boosted the abundance of Akkermansia muciniphila and Lactobacillus, species known to strengthen the gut barrier and produce anti-inflammatory metabolites.

Inflammatory Control and Metabolomic Shift

PCPs suppressed pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α) while boosting the anti-inflammatory cytokine IL-10. They also upregulated tight junction proteins (ZO-1, occludin, and claudin), which act like the "mortar" between intestinal cells to prevent leakage. Metabolomic analysis identified a shift back toward a healthy state, specifically influencing pathways related to steroid hormone biosynthesis and carbohydrate metabolism.

Conclusion

PCPs significantly ameliorate UC symptoms in mice by reshaping the gut microbiota and restoring inflammatory balance. Fecal transplants from PCP-treated donors produced therapeutic effects similar to direct PCP treatment, providing definitive proof of the microbial mechanism. While these results are robust in a mouse model, future work should focus on clinical translation in humans and identifying the exact molecular interactions between specific PCPs and the bacterial species they promote.

Summary updated

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized inflammatory imbalance, intestinal epithelial mucosal damage, and dysbiosis of the gut microbiota. <i>Polygonatum cyrtonema</i> polysaccharides (PCPs) can regulate gut microbiota and inflammation. Here, the different doses of PCPs were administered to dextran sodium sulfate-induced UC mice, and the effects of the whole PCPs were compared with those of the fractionated fractions PCP-1 (19.9 kDa) and PCP-2 (71.6 and 4.2 kDa). Additionally, an antibiotic cocktail was administered to UC mice to deplete the gut microbiota, and PCPs were subsequently administered to elucidate the potential role of the gut microbiota in these mice. The results revealed that PCP treatment significantly optimized the lost weight and shortened colon, restored the balance of inflammation, mitigated oxidative stress, and restored intestinal epithelial mucosal damage. And, the PCPs exhibited superior efficacy in ameliorating these symptoms compared with PCP-1 and PCP-2. However, depletion of the gut microbiota diminished the therapeutic effects of PCPs in UC mice. Furthermore, fecal transplantation from PCP-treated UC mice to new UC-afflicted mice produced therapeutic effects similar to PCP treatment. So, PCPs significantly ameliorated the symptoms, inflammation, oxidative stress, and intestinal mucosal damage in UC mice, and gut microbiota partially mediated these effects.
BibTeX
@inproceedings{lin2024polygonatum,
  author = {Chaoyou Lin and Song Dawei and Shangwen Wang and Yunfei Chu and Changxing Chi and Sining Jia and Mengyi Lin and Chenbei He and Chengxi Jiang and Fanghua Gong and Qiongzhen Chen},
  title = {{Polygonatum cyrtonema polysaccharides reshape the gut microbiota to ameliorate dextran sodium sulfate-induced ulcerative colitis in mice}},
  booktitle = {Frontiers in Pharmacology},
  year = {2024},
  doi = {10.3389/fphar.2024.1424328},
}
Figure